fbpx Skip to main content

FRIDAY, Oct. 16, 2020 (HealthDay News) — Women who experience their first myocardial infarction (MI) at ≤50 years of age are less likely than men to undergo coronary revascularization or be treated with guideline-directed medical therapies, according to a study published online Oct. 13 in the European Heart Journal.

Ersilia M. DeFilippis, M.D., from Harvard Medical School in Boston, and colleagues examined sex differences in individuals who experienced their first MI at a young age. Data were included from 2,097 individuals (404 female) who had a Type 1 MI at ≤50 years between 2000 and 2016.

The researchers found that men and women had similar risk factor profiles, although women were more likely to have diabetes (23.7 versus 18.9 percent). The likelihood of undergoing invasive coronary angiography and coronary revascularization was lower for women (93.5 versus 96.7 percent and 82.1 versus 92.6 percent). The likelihood of having MI with nonobstructive coronary disease on angiography was also increased for women (10.2 versus 4.2 percent). Women were significantly less likely to be discharged with aspirin, beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers, and statins. No significant difference was seen in in-hospital mortality; a higher all-cause mortality rate was seen among women who survived to hospital discharge (adjusted hazard ratio, 1.63).

This study “demonstrates the continued need — and obligation — to study and improve the incidence and mortality trajectory of cardiovascular disease in the young, especially women,” write the authors of an accompanying editorial.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text

You May Also Like::  Contact Allergens in Feminine Hygiene Wipes and Vulvar Contact Dermatitis

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More